Authors
Yuhang Deng, Fenghao Xie, Wenqing Wu, Di Wang, Yongjie Guan, Qitong Zhang, Fengmei Hu, Haoqin Jiang, Ming Guan
Published in
ACS omega. Volume 11. Issue 6. Pages 9138-9144. Feb 17, 2026. Epub Feb 02, 2026.
Abstract
Monoclonal antibodies hold significant promise for the treatment of Alzheimer's disease (AD), and donanemab is the latest therapeutic human IgG1 antibody approved for clinical use. The development and pharmacokinetic evaluation of antibody drugs necessitate accurate quantification. Currently, immunoassays are mainly used by clinical trials to measure those antibody drugs for AD. However, immunoassays often face limitations such as cross-reactivity, insufficient specificity, and poor interlaboratory comparability. Therefore, we developed a robust liquid chromatography-tandem mass spectrometry (LC-MS/MS) method incorporating immunoaffinity enrichment for serum donanemab. This LC-MS/MS method can effectively distinguish donanemab from endogenous immunoglobulins in serum and have sufficient sensitivity. This developed LC-MS/MS method involved: (1) immunoaffinity capture and enrichment of serum donanemab and its internal standard using protein G-conjugated magnetic beads; (2) tryptic digestion of the purified antibodies; and (3) targeted quantification of unique signature peptides via LC-MS/MS for quantification. In conclusion, this method demonstrated acceptable performance, including a lower limit of quantification of 0.1 μg/mL, satisfactory precision (total CV < 8%), high accuracy (95-100% recovery), and a wide linear range (0.2-200 μg/mL), and is the first reported LC-MS/MS method for donanemab offering an alternative for therapeutic antibody monitoring of monoclonal antibody drugs.
PMID:
41726622
Bibliographic data and abstract were imported from PubMed on 10 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 12
- Comments 0